海南医科大学学报2025，Vol.31Issue(11)：863-871,9.DOI:10.13210/j.cnki.jhmu.20250227.003
二甲双胍治疗生长激素细胞瘤的机制研究进展
Advances in the mechanistic study of metformin in the treatment of growth hormone cell tumors
摘要
Abstract
Growth hormone cell tumors are neoplastic lesions with a combination of endocrine and occupying effects.Transs-phenoidal sinus surgical resection is the first-line treatment option for growth hormone cell tumors,and its postoperative endocrine low remission rate and high tumor recurrence rate is one of the serious challenges in the treatment process.Drugs such as dopamine receptor agonists,somatostatin receptor ligands,and growth hormone receptor antagonists are often used as the main adjuvant therapy in the clinic,but the therapeutic efficacy still has obvious individual differences.Metformin,as a first-line hypoglycemic drug,has anti-tumor properties while lowering glucose and improving insulin sensitivity,mainly through the activation of adenos-ine monophosphate-activated protein kinase-dependent and non-dependent pathways to slow down tumor growth and proliferation,and the inhibition of insulin-insulin growth factor 1-growth hormone endocrine pathway to improve the peripheral effects to further achieve anti-tumor effects.This paper discusses the mechanism of metformin's regulation of the cellular microenvironment and hor-mone synthesis and secretion in growth hormone cell tumors,and provides new ideas for the study and selection of drugs against growth hormone cell tumors.关键词
二甲双胍/生长激素细胞瘤/单磷酸腺苷活化蛋白激酶/生长激素/胰岛素/胰岛素生长因子-1Key words
Metformin/Growth hormone cell tumors/Adenosine monophosphate-activated protein kinase/Growth hor-mone/Insulin/Insulin growth factor-1分类
临床医学引用本文复制引用
许丹霞,陈慧..二甲双胍治疗生长激素细胞瘤的机制研究进展[J].海南医科大学学报,2025,31(11):863-871,9.基金项目
This study was supported by National Natural Science Foundation of China(31670518) 国家自然科学基金资助项目(31670518) （31670518）
